Key result
A serum biomarker panel of TNF-α, AGEs, creatinine, and insulin distinguished diabetic diastolic dysfunction from normal echocardiography with an AUC of 0.913 (78.7% sensitivity, 100% specificity).
Why the study?
To assess the role of serum biomarkers in the early prediction of diabetic cardiomyopathy.
Does a panel of serum biomarkers (AGEs, TNF-α, IL-6, IGFBP-7, creatinine, insulin) accurately detect early diabetic cardiomyopathy in patients with Type 2 diabetes mellitus?
Case-Control
Does a panel of serum biomarkers (AGEs, TNF-α, IL-6, IGFBP-7, creatinine, insulin) accurately detect early diabetic cardiomyopathy in patients with Type 2 diabetes mellitus?
Effect estimate: AUC 0.913
A specific panel of serum biomarkers including AGEs, IL-6, TNF-α, insulin, and creatinine shows high diagnostic accuracy for the early detection of diastolic dysfunction in patients with Type 2 diabetes.
Biomarker panels may aid early diabetic cardiomyopathy detection in T2D; leaves open need for larger prospective validation before clinical adoption.
No takes yet. Share an insight, caveat, or question.
Abdelrahman et al. (2021) conducted a case-control in Diabetic cardiomyopathy in Type 2 diabetes mellitus. Serum biomarkers (AGEs, TNF-α, IL-6, IGFBP-7, creatinine, insulin) vs. Normal echocardiography or healthy controls was evaluated on Distinguishing diabetic diastolic dysfunction (DM-DD) from normal echocardiography (DM-N) (AUC 0.913). A serum biomarker panel of TNF-α, AGEs, creatinine, and insulin distinguished diabetic diastolic dysfunction from normal echocardiography with an AUC of 0.913 (78.7% sensitivity, 100% specificity).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: